Roger Perlmutter, Merck
July 30, 2019 08:09 AM EDTUpdated 12:07 PM
Bioregnum
Opinion

Do you want to see what win­ning big in the R&D race looks like in the Big Phar­ma league?

Mer­ck $MRK of­fered a sim­ple les­son in the eco­nom­ics of win­ning a megablock­buster R&D race to­day. And it shouldn’t be missed by any­one.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE
TRENDING NOW

Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Re­gen­eron and Mam­moth strike $100M deal to pair tiny CRISPR ed­i­tors with new de­liv­ery idea

As­traZeneca’s Pas­cal So­ri­ot says new rise in pay is ‘re­al­ly about’ po­ten­tial suc­ces­sor

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

Bio­Mar­in's Roc­ta­vian strug­gles con­tin­ue. Is a di­vest­ment in the fu­ture?

A service from the Financial Times